Exhibits
10-K
from 10-K
146 pages
10-K
03/20/25
EX-4.2
from 10-K
3 pages
Description of the Registrant’s Securities
03/20/25
EX-10.13
from 10-K
4 pages
Second Amendment to Lease Agreement
03/20/25
EX-10.18
from 10-K
3 pages
Certain Information Has Been Excluded From This Exhibit Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. the Omitted Portions of This Document Are Indicated by [***]
03/20/25
EX-10.19
from 10-K
15 pages
Verastem, Inc., and Chugai Pharmaceutical Co., Ltd. Second Amendment to License Agreement
03/20/25
EX-10.20
from 10-K
3 pages
Third Amendment to License Agreement for Cki27
03/20/25
EX-10.44
from 10-K
85 pages
Collaboration and Option Agreement by and Between Verastem, Inc. and Genfleet Therapeutics (Shanghai), Inc. Dated as of August 24, 2023
03/20/25
EX-10.45
from 10-K
5 pages
Verastem, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Agreement
03/20/25
EX-19.1
from 10-K
9 pages
Report furnished to security holders
03/20/25
EX-21.1
from 10-K
1 page
Subsidiaries of the registrant
03/20/25
EX-23.1
from 10-K
~5
pages
Consent of expert or counsel
03/20/25
EX-31.1
from 10-K
1 page
Management certification of annual or quarterly disclosure
03/20/25
EX-31.2
from 10-K
1 page
Management certification of annual or quarterly disclosure
03/20/25
EX-32.1
from 10-K
1 page
Management certification of financial report
03/20/25
EX-32.2
from 10-K
1 page
Management certification of financial report
03/20/25
EX-99.1
from 10-K
10 pages
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
03/20/25
